Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361815143> ?p ?o ?g. }
- W4361815143 abstract "<div>AbstractPurpose:<p>Somatostatin analogues (SSA) are efficacious and safe treatments for a variety of neuroendocrine tumors, especially pituitary neuroendocrine tumors (PitNET). Their therapeutic effects are mainly mediated by somatostatin receptors SST<sub>2</sub> and SST<sub>5</sub>. Most SSAs, such as octreotide/lanreotide/pasireotide, are either nonselective or activate mainly SST<sub>2</sub>. However, nonfunctioning pituitary tumors (NFPTs), the most common PitNET type, mainly express SST<sub>3</sub> and finding peptides that activate this particular somatostatin receptor has been very challenging. Therefore, the main objective of this study was to identify SST<sub>3</sub>-agonists and characterize their effects on experimental NFPT models.</p>Experimental Design:<p>Binding to SSTs and cAMP level determinations were used to screen a peptide library and identify SST<sub>3</sub>-agonists. Key functional parameters (cell viability/caspase activity/chromogranin-A secretion/mRNA expression/intracellular signaling pathways) were assessed on NFPT primary cell cultures in response to SST<sub>3</sub>-agonists. Tumor growth was assessed in a preclinical PitNET mouse model treated with a SST<sub>3</sub>-agonist.</p>Results:<p>We successfully identified the first SST<sub>3</sub>-agonist peptides. SST<sub>3</sub>-agonists lowered cell viability and chromogranin-A secretion, increased apoptosis <i>in vitro</i>, and reduced tumor growth in a preclinical PitNET model. As expected, inhibition of cell viability in response to SST<sub>3</sub>-agonists defined two NFPT populations: responsive and unresponsive, wherein responsive NFPTs expressed more SST<sub>3</sub> than unresponsive NFPTs and exhibited a profound reduction of MAPK, PI3K-AKT/mTOR, and JAK/STAT signaling pathways upon SST<sub>3</sub>-agonist treatments. Concurrently, <i>SSTR3</i> silencing increased cell viability in a subset of NFPTs.</p>Conclusions:<p>This study demonstrates that SST<sub>3</sub>-agonists activate signaling mechanisms that reduce NFPT cell viability and inhibit pituitary tumor growth in experimental models that expresses SST<sub>3</sub>, suggesting that targeting this receptor could be an efficacious treatment for NFPTs.</p></div>" @default.
- W4361815143 created "2023-04-05" @default.
- W4361815143 creator A5001409891 @default.
- W4361815143 creator A5003412241 @default.
- W4361815143 creator A5005394810 @default.
- W4361815143 creator A5005565612 @default.
- W4361815143 creator A5006658221 @default.
- W4361815143 creator A5009563981 @default.
- W4361815143 creator A5015262459 @default.
- W4361815143 creator A5017193906 @default.
- W4361815143 creator A5021832421 @default.
- W4361815143 creator A5022065658 @default.
- W4361815143 creator A5026878336 @default.
- W4361815143 creator A5027427939 @default.
- W4361815143 creator A5028840331 @default.
- W4361815143 creator A5031937268 @default.
- W4361815143 creator A5033524062 @default.
- W4361815143 creator A5044053354 @default.
- W4361815143 creator A5047715168 @default.
- W4361815143 creator A5058135917 @default.
- W4361815143 creator A5059027410 @default.
- W4361815143 creator A5062376723 @default.
- W4361815143 creator A5066697337 @default.
- W4361815143 creator A5067878963 @default.
- W4361815143 creator A5088589605 @default.
- W4361815143 date "2023-03-31" @default.
- W4361815143 modified "2023-09-27" @default.
- W4361815143 title "Data from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors" @default.
- W4361815143 doi "https://doi.org/10.1158/1078-0432.c.6530364.v1" @default.
- W4361815143 hasPublicationYear "2023" @default.
- W4361815143 type Work @default.
- W4361815143 citedByCount "0" @default.
- W4361815143 crossrefType "posted-content" @default.
- W4361815143 hasAuthorship W4361815143A5001409891 @default.
- W4361815143 hasAuthorship W4361815143A5003412241 @default.
- W4361815143 hasAuthorship W4361815143A5005394810 @default.
- W4361815143 hasAuthorship W4361815143A5005565612 @default.
- W4361815143 hasAuthorship W4361815143A5006658221 @default.
- W4361815143 hasAuthorship W4361815143A5009563981 @default.
- W4361815143 hasAuthorship W4361815143A5015262459 @default.
- W4361815143 hasAuthorship W4361815143A5017193906 @default.
- W4361815143 hasAuthorship W4361815143A5021832421 @default.
- W4361815143 hasAuthorship W4361815143A5022065658 @default.
- W4361815143 hasAuthorship W4361815143A5026878336 @default.
- W4361815143 hasAuthorship W4361815143A5027427939 @default.
- W4361815143 hasAuthorship W4361815143A5028840331 @default.
- W4361815143 hasAuthorship W4361815143A5031937268 @default.
- W4361815143 hasAuthorship W4361815143A5033524062 @default.
- W4361815143 hasAuthorship W4361815143A5044053354 @default.
- W4361815143 hasAuthorship W4361815143A5047715168 @default.
- W4361815143 hasAuthorship W4361815143A5058135917 @default.
- W4361815143 hasAuthorship W4361815143A5059027410 @default.
- W4361815143 hasAuthorship W4361815143A5062376723 @default.
- W4361815143 hasAuthorship W4361815143A5066697337 @default.
- W4361815143 hasAuthorship W4361815143A5067878963 @default.
- W4361815143 hasAuthorship W4361815143A5088589605 @default.
- W4361815143 hasConcept C126322002 @default.
- W4361815143 hasConcept C134018914 @default.
- W4361815143 hasConcept C150008808 @default.
- W4361815143 hasConcept C170493617 @default.
- W4361815143 hasConcept C185592680 @default.
- W4361815143 hasConcept C2776297358 @default.
- W4361815143 hasConcept C2777433750 @default.
- W4361815143 hasConcept C2778938600 @default.
- W4361815143 hasConcept C2779371878 @default.
- W4361815143 hasConcept C2779609023 @default.
- W4361815143 hasConcept C2984496839 @default.
- W4361815143 hasConcept C71315377 @default.
- W4361815143 hasConcept C71924100 @default.
- W4361815143 hasConcept C80115893 @default.
- W4361815143 hasConcept C86803240 @default.
- W4361815143 hasConceptScore W4361815143C126322002 @default.
- W4361815143 hasConceptScore W4361815143C134018914 @default.
- W4361815143 hasConceptScore W4361815143C150008808 @default.
- W4361815143 hasConceptScore W4361815143C170493617 @default.
- W4361815143 hasConceptScore W4361815143C185592680 @default.
- W4361815143 hasConceptScore W4361815143C2776297358 @default.
- W4361815143 hasConceptScore W4361815143C2777433750 @default.
- W4361815143 hasConceptScore W4361815143C2778938600 @default.
- W4361815143 hasConceptScore W4361815143C2779371878 @default.
- W4361815143 hasConceptScore W4361815143C2779609023 @default.
- W4361815143 hasConceptScore W4361815143C2984496839 @default.
- W4361815143 hasConceptScore W4361815143C71315377 @default.
- W4361815143 hasConceptScore W4361815143C71924100 @default.
- W4361815143 hasConceptScore W4361815143C80115893 @default.
- W4361815143 hasConceptScore W4361815143C86803240 @default.
- W4361815143 hasLocation W43618151431 @default.
- W4361815143 hasOpenAccess W4361815143 @default.
- W4361815143 hasPrimaryLocation W43618151431 @default.
- W4361815143 hasRelatedWork W1571642116 @default.
- W4361815143 hasRelatedWork W2060030424 @default.
- W4361815143 hasRelatedWork W2105705536 @default.
- W4361815143 hasRelatedWork W2152461924 @default.
- W4361815143 hasRelatedWork W2166587323 @default.
- W4361815143 hasRelatedWork W2323187465 @default.
- W4361815143 hasRelatedWork W2797741642 @default.
- W4361815143 hasRelatedWork W3028940269 @default.
- W4361815143 hasRelatedWork W4361815140 @default.
- W4361815143 hasRelatedWork W4361815143 @default.
- W4361815143 isParatext "false" @default.